Dihexa is a synthetic peptide derived from angiotensin IV, originally designed in academic laboratories to promote synaptogenesis, the formation of new connections between brain cells. In animal and laboratory models it has been studied for memory and learning, where it appears extraordinarily potent at driving synaptic growth. It is important to be clear from the outset: Dihexa has not been approved by any major regulator, has never completed a human clinical trial, and its human safety profile is unknown. At Menscape Clinic in Bangkok we present it here for education only. It is a genuinely experimental, largely preclinical molecule, and our physicians do not currently offer it as a routine cognitive-health treatment.
/)
Medically reviewed by Dr. Tuksaorn Suriyakan (Ping), Anti-Aging & Regenerative Medicine Physician
8 years of experience
Our solutions for Cognitive Health
Indications evaluated in research, listed in order of current evidence weight. Suitability is determined case-by-case.
Dihexa is a small synthetic peptide (also referred to as PNB-0408 or N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) derived from angiotensin IV, a fragment of the angiotensin signalling system. It was engineered in academic research to be more stable than angiotensin IV and to cross the blood-brain barrier, so that its effects on brain cells could be studied. In preclinical assays it has been reported as exceptionally potent at promoting synapse formation. We want to be direct about the limits of this evidence. The body of work is based on cell cultures and animal models, several of the foundational laboratory papers were retracted in 2025 following a research-integrity finding, and Dihexa itself has never been tested in a completed human clinical trial. It is best understood as an experimental, research-stage compound rather than an established therapy.
/)
In laboratory models, Dihexa is described as acting on the hepatocyte growth factor (HGF) and its receptor c-Met. By potentiating this pathway, it is reported to encourage spinogenesis and synaptogenesis, the growth of new dendritic spines and synapses in the hippocampus, a brain region central to memory. This mechanism is the source of both the interest in Dihexa and a genuine safety caution: the HGF/c-Met pathway is also one of the better-characterised pathways in cancer biology, and activating it long-term has not been studied for cancer-related risk in any species. The mechanism described here is drawn from preclinical research and should be read as a working hypothesis, not a demonstrated effect in people.
/)
In research settings Dihexa has been examined in animal models of memory impairment and neurodegeneration. That is very different from a clinical indication. Because there is no human safety data, no established dose, and no regulatory approval, Dihexa is not appropriate as a self-directed nootropic or wellness supplement. It should be considered off-limits for anyone with a personal or family history of cancer, anyone who is pregnant, breastfeeding or trying to conceive, and anyone using it without medical oversight. At Menscape we would only ever discuss a compound like this in the context of a full medical consultation, and in most cases we will advise against use given the current evidence.
/)
At Menscape Clinic in Bangkok, cognitive health starts with assessment rather than with experimental peptides: sleep, cardiovascular and metabolic health, hormones, mood and lifestyle, all of which have stronger evidence behind them. We include Dihexa on our site because patients ask about it, and our role is to give an honest, physician-reviewed picture. We do not currently provide Dihexa as a standard treatment. If a patient raises it, our doctors will review the (limited, animal-only) evidence, the unresolved cancer-pathway and safety questions, and the lack of regulatory approval, and will typically steer toward better-supported options. Any decision is made one-to-one with a licensed physician.
/)
Any conversation about Dihexa starts with a physician explaining what the research does and does not yet show — never a sales pitch.
We do not sell Dihexa over the counter or source it from unregulated suppliers, and it is never handed out on request.
Because human safety data is limited or absent, we say so plainly rather than imply a proven or routine treatment.
We treat Dihexa as an experimental, research-stage compound — not a standard program we market or promote.
No. Dihexa has not been approved by the FDA or, to our knowledge, by other major regulators, and there is no approved prescription pathway for it. It has no Investigational New Drug authorisation on file and is sold elsewhere only as a research chemical labelled not for human use. In Thailand and most countries it is not an approved medicine. Menscape presents it for education and does not offer it as a routine treatment.
Not in any completed clinical trial. The available evidence comes from cell cultures and animal models. A separate, related prodrug (fosgonimeton / ATH-1017) was tested in human Alzheimer's trials but did not meet its main endpoint and development was paused. Dihexa itself has no human safety or efficacy data, which is the single most important fact to understand before considering it.
Its safety in humans is unknown. With no completed human trials, there is no established dose, no defined side-effect profile, and no long-term safety data. There is also a specific theoretical concern: Dihexa acts on the HGF/c-Met pathway, which is implicated in several cancers, and no carcinogenicity studies have been done. For these reasons we treat Dihexa with caution and do not recommend unsupervised use.
In preclinical research it has been studied for synaptogenesis (new synapse formation) and for memory and learning in animal models of cognitive impairment. These are research observations, not proven benefits in people. No clinical claim of efficacy in humans can responsibly be made at this time.
Three reasons. First, the human evidence base is effectively absent. Second, several foundational laboratory papers describing how Dihexa works were retracted in 2025 after a research-integrity finding, which weakens the original case for it. Third, its mechanism touches a pathway linked to cancer biology that has never been safety-tested for this use. Together these put Dihexa firmly in the experimental category.
We do not currently offer Dihexa as a standard cognitive-health treatment. If you are interested in it, you are welcome to book a consultation, where our doctors will walk you through the current evidence, the safety questions, and its unapproved status, and discuss better-supported approaches to brain and cognitive health. Any path forward is decided individually with a licensed physician.
/)
Dr. Tuksaorn (Dr. Ping) is an anti-aging and regenerative medicine physician with over 8 years of experience, focused on evidence-based wellness and personalized health programs that combine modern medical science with individualized care.
/)
/)
/)
/)
/)